Gene therapy for T cell regulation

A method to treat a mammal that has cancer, said method comprising administering to said mammal a therapeutic composition comprising:

• (a) a liposome delivery vehicle;
• (b) a first recombinant construct comprising an isolated nucleic acid sequence encoding a superantigen operatively linked to one or more transcription control sequences;
• and
• (c) a second recombinant construct comprising an isolated nucleic acid sequence encoding a cytokine operatively linked to one or more transcription control sequences;
• wherein said nucleic acid sequences encoding said superantigen and said cytokine, respectively, are coexpressed at or adjacent to said cancer;
• and
• wherein coexpression of said superantigen and said cytokine produces a result selected from the group consisting of alleviation of said cancer, reduction of a tumor associated with said cancer, elimination of a tumor associated with said cancer, prevention of metastatic cancer, and stimulation of effector cell immunity against said cancer.

A method to treat a mammal that has cancer, said method comprising:

• (a) removing cells of said mammal;
• (b) transfecting said cells in vitro with a recombinant construct comprising a first isolated nucleic acid sequence encoding a superantigen, and a second isolated nucleic acid sequence encoding a cytokine, said first and second nucleic acid sequences being operatively linked to one or more transcription control sequences;
• and
• (c) reintroducing said transfected cells to said mammal;
• wherein said first and said second nucleic acid sequences encoding said superantigen and said cytokine, respectively, are coexpressed at or adjacent to said cancer;
• and
• wherein coexpression of said superantigen and said cytokine produces a result selected from the group consisting of alleviation of said cancer, reduction of a tumor associated with said cancer, elimination of a tumor associated with said cancer, prevention of metastatic cancer, and stimulation of effector cell immunity against said cancer.

A method to treat a mammal that has cancer, said method comprising:

• (a) removing cells of said mammal;
• ( b) transletting said cells in vitro with a therapeutic composition comprising:
• (i) a first recombinant construct comprising an isolated nucleic acid sequence encoding a superantigen operatively linked to one or more transcription control sequences;
• and
• (ii) a second recombinant construct comprising an isolated nucleic acid sequence encoding a cytokine operatively linked to one or more transcription control sequences;
• and
• (c) reintroducing said transfected cells to said mammal;
• wherein said nucleic acid sequences encoding said superantigen and said cytokine, respectively, are coexpressed at or adjacent to said cancer;
• and
• wherein coexpression of said superantigen and said cytokine produces a result selected from the group consisting of alleviation of said cancer, reduction of a tumor associated with said cancer, elimination of a tumor associated with said cancer, prevention of metastatic cancer, and stimulation of effector cell immunity against said cancer.

A method for increasing effector cell immunity against a cancer in a mammal, said method comprising administering to said mammal a therapeutic composition comprising:

• (a) a liposome delivery vehicle;
• and
• (b) a recombinant construct comprising a first isolated nucleic acid sequence encoding a superantigen;
• and a second isolated nucleic acid sequence encoding a cytokine, said first and second nucleic acid sequences being operatively linked to one or more transcription control sequences;
• wherein said first and said second nucleic acid sequences encoding said superantigen and said cytokine, respectively, are coexpressed at or adjacent to said cancer;
• and
• wherein coexpression of said superantigen and said cytokine results in an increase in effector immunity against said cancer.

A method for increasing effector cell immunity against a cancer in a mammal, said method comprising administering to said mammal a therapeutic composition comprising:

• (a) a liposome delivery vehicle;
• (b) a first recombinant construct comprising an isolated nucleic acid sequence encoding a superantigen operatively linked to one or more transcription control sequences;
• and
• (c) a second recombinant construct comprising an isolated nucleic acid sequence encoding a cytokine operatively linked to one or more transcription control sequences;
• wherein said nucleic acid sequences encoding said superantigen and said cytokine, respectively, are coexpressed at or adjacent to said cancer;
• and
• wherein coexpression of said superantigen and said cytokine results in an increase in effector immunity against said cancer.

A method for increasing effector cell immunity against a cancer in a mammal, said method comprising:

• (a) removing cells of said mammal;
• (b) transfecting said cells in vitro with a recombinant construct comprising a first isolated nucleic acid sequence encoding a superantigen, and a second isolated nucleic acid sequence encoding a cytokine, said first and second nucleic acid sequences being operatively linked to one or more transcription control sequences;
• and
• (c) reintroducing said transfected cells to said mammal;
• wherein said first and said second nucleic acid sequences encoding said superantigen and said cytokine, respectively, are coexpressed at or adjacent to said cancer;
• and
• wherein coexpression of said superantigen and said cytokine results in an increase in effector immunity against said cancer.

A method for increasing effector cell immunity against a cancer in a mammal, said method comprising:

• (a) removing cells of said mammal;
• (b) transfecting said cells in vitro with a therapeutic composition comprising:
• (i) a first recombinant construct comprising an isolated nucleic acid sequence encoding a superantigen operatively linked to one or more transcription control sequences;
• and
• (ii) a second recombinant construct comprising an isolated nucleic acid sequence encoding a cytokine operatively linked to one or more transcription control sequences;
• and
• (c) reintroducing said transfected cells to said mammal;
• wherein said nucleic acid sequences encoding said superantigen and said cytokine, respectively, are coexpressed at or adjacent to said cancer;
• and
• wherein coexpression of said superantigen and said cytokine results in an increase in effector immunity against said cancer.